Beijing-based biotech company EdiGene Inc – that uses genome editing technologies for novel therapeutics and advanced drug discovery solutions – has raised about $15 million in a pre-Series B financing round led by Lilly Asia Ventures (LAV) a venture capital firm from Shanghai, according to an announcement.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
